Betta Pharmaceuticals Co., Ltd.: Carcinoma, Non-Small-Cell Lung trials

The registry lists 39 Carcinoma, Non-Small-Cell Lung studies with Betta Pharmaceuticals Co., Ltd. as lead sponsor. 10 are open to participants now and 2 have results posted.

Phase 1 12Phase 2 20Phase 3 7Phase 4 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung CancerRecruitingNCT07806604
• Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT07435038Phase 1/2
• Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Phase 2
• A Phase I Study of CFT8919 in Patients With Advanced NSCLCRecruitingNCT06641609Phase 1
• Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsRecruitingNCT06041776Phase 3
• Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruitingNCT06015568Phase 1
• BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT05393466Phase 1/2
• Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingNCT05341583Phase 3
• Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Phase 1/2
• Expanded Access to Ensartinib for Participants With ALK+ NSCLCAvailableNCT04146571
• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedNCT01625234Phase 1/2Results posted
• Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Phase 3Results posted
• A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsStatus unknownNCT05329298Phase 1/2
• X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesStatus unknownNCT04415320Phase 2
• D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedNCT04206072Phase 2/3
• CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).Status unknownNCT03848611Phase 2
• Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung CancerStatus unknownNCT03749213Phase 2
• A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.CompletedNCT03510611Phase 1
• Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung CancerStatus unknownNCT03396185Phase 2
• Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung CancerStatus unknownNCT03349203Phase 2
• X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With CrizotinibActive, not recruitingNCT03215693Phase 2
• Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
• Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLCStatus unknownNCT02929290Phase 1
• Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsCompletedNCT02914990Phase 1
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Phase 3
• Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With ChemotherapyCompletedNCT02486354Phase 3
• Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutationStatus unknownNCT02448797Phase 3
• High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon MutationStatus unknownNCT02404675Phase 4
• Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Phase 2
• Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLCStatus unknownNCT02194556Phase 4
• Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIStatus unknownNCT02066870Phase 1
• Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic InsufficiencyStatus unknownNCT02062515Phase 2
• High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable DiseaseStatus unknownNCT02027090Phase 2
• Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR MutationStatus unknownNCT01929200Phase 2
• Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC PatientsStatus unknownNCT01843647Phase 2
• Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib TreatmentStatus unknownNCT01707329Phase 2
• Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable DiseaseStatus unknownNCT01690390Phase 2
• First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated PatientsStatus unknownNCT01646450Phase 4
• Dose Escalation Of Icotinib In Previously Treated Patients With Routine DoseCompletedNCT01465243Phase 4